PM
OKUR

Prosight Management’s OnKure Therapeutics OKUR Stock Holding History

Prosight Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.92M Buy
2,154,381
+1,337,472
+164% +$4.13M 1.46% 21
2025
Q4 		$2.37M Buy
816,909
+548,950
+205% +$1.64M 0.49% 31
2025
Q3 		$737K Buy
267,959
+108,267
+68% +$268K 0.17% 36
2025
Q2 		$382K Sell
159,692
-26,878
-14% -$70.5K 0.09% 37
2025
Q1 		$802K Buy
186,570
+122,816
+193% +$691K 0.26% 34
2024
Q4 		$548K Buy
+63,754
New +$965K 0.15% 36
2021
Q3 		– Sell
-5,493
Closed -$513K – 54
2021
Q2 		$513K Buy
+5,493
New +$613K 0.32% 42

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Prosight Management's OKUR Position: Q1 2026 in Review

Prosight Management increased its OnKure Therapeutics (OKUR) stake by 164% in Q1 2026, buying an estimated $4.13M and bringing the position to 2,154,381 shares worth $8.92M. The position accounts for 1.46% of the portfolio, ranked #21.

Prosight Management first reported a position in OKUR in Q2 2021 and has held it in 7 quarters since. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Prosight Management held 2,154,381 shares of OnKure Therapeutics worth $8.92M as of Q1 2026.
  • Prosight Management bought 1,337,472 OnKure Therapeutics shares in Q1 2026, an estimated $4.13M.
  • OnKure Therapeutics made up 1.46% of Prosight Management's portfolio in Q1 2026, its #21 holding.
  • Prosight Management first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.